Abstract
Razaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa. The molecule contains a 1,2-benzisoxazole structure. After oral administration of [14C]razaxaban to intact and bile duct-cannulated rats (300 mg/kg) and dogs (20 mg/kg), metabolism followed by biliary excretion was the major elimination pathway in both species, accounting for 34 to 44% of the dose, whereas urinary excretion accounted for 3 to 13% of the dose. Chromatographic separation of radioactivity in urine, bile, and feces of rats and dogs showed that razaxaban was extensively metabolized in both species. Metabolites were identified on the basis of liquid chromatography/tandem mass spectrometry and comparison with synthetic standards. Among the 12 metabolites identified, formation of an isoxazole-ring opened benzamidine metabolite (M1) represented a major metabolic pathway of razaxaban in rats and dogs. However, razaxaban was the major circulating drug-related component (>70%) in both species, and M1, M4, and M7 were minor circulating components. In addition to the in vivo observations, M1 was formed as the primary metabolite in rat and dog hepatocytes and in the rat liver cytosolic fraction. The formation of M1 in the rat liver fraction required the presence of NADH. Theses results suggest that isoxazole ring reduction, forming a stable benzamidine metabolite (M1), represents the primary metabolic pathway of razaxaban in vivo and in vitro. The reduction reaction was catalyzed by NADH-dependent reductase(s) in the liver and possibly by intestinal microflora on the basis of the recovery of M1 in feces of bile duct-cannulated rats.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.107.018416.
-
ABBREVIATIONS: razaxaban, BMS-561389, DPC906, 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-(2′-dimethyl aminomethylimidazol-1-yl)phenyl]-1H-pyrazole-5-carboxyamide; HPLC, high performance liquid chromatography; NMR; nuclear magnetic resonance; MS, mass spectrometry; DMF, dimethylformamide; TFA, trifluoroacetic acid; ESI, electrospray ionization; BDC, bile duct cannulated; LC, liquid chromatography; MS/MS, tandem mass spectrometry; ABT-418, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; D2624, N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide; AG7088, trans-(4S,2′R,5′S,3′′′S)-4-{2′-4-(4-fluorobenzyl)-6′-methyl-5′-[(5″-methylisoxazole-3′-carbonylamino]-4-oxoheptanoylamino}-5-(2′′′-oxopyrrolidin-3′′′-yl)pent-2-enoic acid ethyl ester.
-
↵1 Current affiliation: Amgen, Department of Pharmacokinetics and Drug Metabolism, One Amgen Center Drive, Thousand Oaks, CA 91320.
- Received August 21, 2007.
- Accepted October 31, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|